Durvalumab vs Upadacitinib

## Durvalumab vs Upadacitinib: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Upadacitinib**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Upadacitinib**: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Upadacitinib — 9-14 hours.

## Chemical Properties

**Molecular Formula**: Durvalumab — N/A; Upadacitinib — C17H19F3N6O.

**Molecular Weight**: Durvalumab — N/A; Upadacitinib — 380.3700 g/mol.

**Type**: Durvalumab — Antibody; Upadacitinib — Small molecule.